The Parkinson’s field is littered with clinical failures and another candidate, UCB’s minzasolmin, is the latest to fall in the quest for a disease modifying treatment.
UCB’s Parkinson’s Drug Stalls As Curtain Comes Down On ORCHESTRA
Almost three years to the day, Novartis and UCB heralded a pact that could have been worth $1.5bn to the Brussels-based group for a first-in-class, small-molecule, alpha-synuclein misfolding inhibitor for Parkinson’s disease. However, after a Phase IIa fail, the development of minzasolmin has been terminated.
More from Clinical Trials
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
More from Business
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.